Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms
It might appear as though the private biotech sector is approaching a thaw. In recent weeks, a Flagship startup raised $273 million, an RNA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
